Clinical Trial Update: A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two Janssen investigational agents (JNJ-73763989 and JNJ-56136379) in virologically suppressed adults with chronic hepatitis B. The reg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-56136379
• JNJ-73763989
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2024-07-03